Whether it’s cost-of-goods or build-versus-buy analysis, eXmoor Pharma’s Harvey Branton, Evelien Stalmeijer and Ruxandra Comisel say a clear understanding of the end goal is key to develop predictive models for cell and gene therapy manufacturing.
Shutterstock
Whether it’s cost-of-goods or build-versus-buy analysis, eXmoor Pharma’s Harvey Branton, Evelien Stalmeijer and Ruxandra Comisel say a clear understanding of the end goal is crucial to develop useful predictive models for cell and gene therapy manufacturing.
The week's biggest stories from this industry, direct to your inbox.
